Research Topics
| MARK MCCLAINSummaryAffiliation: Vanderbilt University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Analysis of a beta-helical region in the p55 domain of Helicobacter pylori vacuolating toxinSusan E Ivie
Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
BMC Microbiol 10:60. 2010..To test this hypothesis, we introduced eight deletion mutations (each corresponding to a single coil within a beta-helical segment spanning VacA amino acids 433-628) into the H. pylori chromosomal vacA gene...
Genome sequence analysis of Helicobacter pylori strains associated with gastric ulceration and gastric cancerMark S McClain
Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 2605, USA
BMC Genomics 10:3. 2009..In this study, we analyzed the genome sequences of an H. pylori strain (98-10) isolated from a patient with gastric cancer and an H. pylori strain (B128) isolated from a patient with gastric ulcer disease...
Functional analysis of neutralizing antibodies against Clostridium perfringens epsilon-toxinMark S McClain
Department of Medicine, Division of Infectious Diseases, A2200 Medical Center North, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Infect Immun 75:1785-93. 2007..Identifying the epitopes recognized by these neutralizing antibodies constitutes an important first step in the development of therapeutic agents that could be used to counter the effects of the epsilon-toxin...
Mapping of a domain required for protein-protein interactions and inhibitory activity of a Helicobacter pylori dominant-negative VacA mutant proteinVictor J Torres
Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Infect Immun 74:2093-101. 2006....
Research Grants
- Inhibitors to Clostridium perfrigens epsilon toxinMARK MCCLAIN; Fiscal Year: 2007....
- Inhibition of Clostridium perfringens epsilon toxinMark S McClain; Fiscal Year: 2010..Currently, there is no countermeasure approved for use in humans and the specific aims of this proposal are designed to develop inhibitors of epsilon toxin activity. ..
